Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of QM1114-DP for moderate to severe glabellar lines has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• To Severe Glabellar Lines

Drugs mentioned

• QM1114-DP

Snippet

Sponsor: Galderma R&D | Conditions: Moderate to Severe Glabellar Lines | Phase 3 | Status: COMPLETED